[{"data":1,"prerenderedAt":159},["ShallowReactive",2],{"drug-brinzolamide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":33,"contraindications":57,"warnings":67,"renal":75,"monitoring":76,"interactions":77,"review":78,"examples":81,"atc":87,"iran":89,"usApproval":101,"links":107,"populations":124},"brinzolamide",1,{"fa":7,"en":8},"برینزولامید","Brinzolamide","sensory-organs",{"fa":11,"en":12},"مهارکننده کربنیک انیدراز (چشمی)","Carbonic anhydrase inhibitor (ophthalmic)",[14],{"name":15,"market":16},"Azopt","US",[18,19,7],"azopt","آزوپت",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":28,"refs":29},"drops","eye-drops","ophthalmic","1% eye suspension",{"amount":5,"unit":27,"perUnit":27},"drop",[16],[30],{"source":31,"section":32},"fda-azopt","3",[34],{"id":35,"disease":36,"label":37,"population":40,"type":44,"unit":27,"dose":45,"refs":47,"notes":50},"glc","glaucoma",{"fa":38,"en":39},"گلوکوم زاویه باز یا فشار بالای چشم — یک قطره در چشم مبتلا ۳ بار در روز","Open-angle glaucoma or ocular hypertension — 1 drop in the affected eye(s) three times daily",{"minAge":41},{"value":42,"unit":43},18,"year","fixed",{"perDose":5,"dosesPerDay":46},3,[48],{"source":31,"section":49},"2",[51],{"text":52,"refs":55},{"fa":53,"en":54},"پیش از مصرف تکان داده شود؛ با سایر قطره‌ها دست‌کم ۱۰ دقیقه فاصله.","Shake well; separate other eye drops by at least 10 min.",[56],{"source":31,"section":49},[58],{"id":59,"severity":60,"text":61,"refs":64},"hyper","block",{"fa":62,"en":63},"حساسیت به اجزای فرآورده.","Hypersensitivity to any component.",[65],{"source":31,"section":66},"4",[68],{"text":69,"refs":72},{"fa":70,"en":71},"سولفونامید است (واکنش‌های شدید سولفا)؛ آسیب اندوتلیوم قرنیه؛ نارسایی شدید کلیه توصیه نمی‌شود؛ گلوکوم زاویه بسته حاد؛ لنز تماسی.","Sulfonamide (severe sulfa reactions); corneal endothelium; not recommended in severe renal impairment; acute angle-closure glaucoma; contact lenses.",[73],{"source":31,"section":74},"5",[],[],[],{"status":79,"reviewer":80,"date":80},"unverified",null,[82],{"regimen":35,"formulation":22,"input":83,"expect":86},{"ageYears":84,"weightKg":85},60,70,{"perDose":5},[88],"S01EC04",{"status":90,"forms":91,"refs":96},"registered",[92],{"code":93,"en":94,"fa":95},"01930","BRINZOLAMIDE 1% OPH DROP","قطره چشمی برینزولامید ۱ درصد",[97],{"source":98,"section":99,"url":100},"darooyab-generic","G-1566\u002FBrinzolamide","https:\u002F\u002Fwww.darooyab.ir\u002FG-1566\u002FBrinzolamide",{"kind":102,"refs":103,"id":106},"NDA",[104],{"source":31,"section":105},"SPL approval \u002F marketing category","NDA020816",[108,111,115,119,122],{"kind":109,"url":110,"label":106},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=020816",{"kind":112,"url":113,"label":114},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=0afb6589-51ba-432c-aed1-20a12d5d3455","FDA Azopt",{"kind":116,"url":117,"label":118},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601233.html","Brinzolamide Ophthalmic",{"kind":120,"url":121,"label":88},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=S01EC04",{"kind":123,"url":100,"label":8},"darooyab",{"pregnancy":125,"lactation":134,"pediatric":142,"geriatric":150},{"level":126,"text":127,"quote":130,"refs":131},"caution",{"fa":128,"en":129},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate and well-controlled studies in pregnant women to inform drug-associated risk.",[132],{"source":31,"section":133},"8.1",{"level":126,"text":135,"quote":138,"refs":139},{"fa":136,"en":137},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of brinzolamide in human milk, the effects on the breastfed infant, or the effects on milk production.",[140],{"source":31,"section":141},"8.2",{"level":126,"text":143,"quote":146,"refs":147},{"fa":144,"en":145},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","A 3-month controlled clinical study was conducted in which AZOPT was dosed only twice a day in pediatric patients 4 weeks to 5 years of age.",[148],{"source":31,"section":149},"8.4",{"level":151,"text":152,"quote":155,"refs":156},"ok",{"fa":153,"en":154},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness have been observed between elderly and younger patients.",[157],{"source":31,"section":158},"8.5",1792444383626]